Resmetirom Shows Early Results in 712 Real-World Patients

The first approved MASH drug finally has a real-world report card. At the EASL Congress 2026 (May 27-30, Barcelona), a real-world cohort of 712 patients treated with resmetirom outside clinical trials, followed a mean of 5.7 months, showed that roughly 40 to 47 percent met response thresholds across liver stiffness, ALT, or the FAST composite biomarker, improvements that arrived months earlier than the 52-week readout the approval trial was built on.

The response thresholds deserve their own sentence because they are the ones clinicians actually watch. ALT improvement of 17 U/L from baseline or 20 percent, liver stiffness reduction of 25 percent, and the FAST score, a composite of elastography, AST-to-platelet ratio, and age, are monitoring tools a hepatologist uses between visits, and the real-world cohort moved on all three axes.

The trial-to-clinic translation is the study’s real claim. Resmetirom won approval on biopsy endpoints, MASH resolution and fibrosis improvement measured in liver tissue, but no clinic biopsies annually, so the question every prescriber had was whether the trial’s tissue success would show up in the biomarkers the clinic actually measures, and 712 routine patients say it does.

The cardiovascular layer was the congress’s strategic surprise. In a secondary analysis of the MAESTRO program, among statin-naive patients on the 100 mg dose with baseline Lp(a) at or above 50 mg/dL, 62.5 percent dropped below that threshold by week 52, and lipoprotein(a) is the lipid statins famously cannot move, which quietly repositions a liver drug inside cardiology’s unresolved territory.

The cirrhosis data extended the map at the edges. In the two-year compensated MASH cirrhosis cohort, the ANTICIPATE-NASH risk score classified 75 percent of patients as high-risk at baseline and 54.5 percent at year two, and liver-related events occurred exclusively in patients who started with elevated scores, a stratification signal that will shape a dedicated trial in that population.

The combination question came up and got answered in the direction prescribers hoped. Real-world data show added liver benefit when resmetirom is used alongside GLP-1 agents, with no clinically significant drug-drug interactions, which matters because the two drug classes work from opposite ends, the GLP-1 on systemic metabolic load and weight, the resmetirom on hepatic fat and fibrosis signaling.

The mechanism reminder keeps the biology straight. Resmetirom is a liver-directed thyroid hormone receptor-beta agonist, approved for noncirrhotic MASH with moderate-to-advanced fibrosis, to be used alongside diet and exercise, and its label does not include cirrhosis, which is exactly why the compensated-cirrhosis cohort data are labeled exploratory rather than practice-changing.

The honest limits are the ones real-world evidence always carries. No biopsies were taken, so the biomarker responses are surrogates for the tissue endpoints that matter, follow-up is short at a mean of 5.7 months, and treated patients were selected for eligibility rather than randomized, so selection bias rides along with every percentage point.

The Lp(a) finding needs its own guardrail. A post-hoc secondary analysis in statin-naive patients is hypothesis-generating, not an indication, and no clinician should prescribe resmetirom for lipids, but the finding reframes the drug’s ceiling: if a cardiovascular outcomes trial confirms it, the same prescription would be treating the leading cause of death in MASH patients.

The cost-effectiveness context is part of the real story. A DDW 2026 Markov modeling study compared resmetirom, semaglutide, and tirzepatide over a lifetime horizon and found high-dose tirzepatide dominated the cost-effectiveness ranking while all three beat no treatment, which is the economic backdrop against which every real-world response rate will be weighed by payers.

For a reader already on resmetirom, the practical read is calibration. The biomarker response thresholds in this cohort are the numbers a monitoring visit will reference, six months is a reasonable early checkpoint rather than a verdict point, and the diet-and-exercise co-therapy on the label is not fine print, it is the mechanism’s daily fuel.

For a reader wondering whether to ask about the drug, the honest answer runs through staging. Resmetirom belongs to noncirrhotic MASH with F2-F3 fibrosis, which means the FIB-4-and-elastography pathway this site keeps describing is the doorway the prescription sits behind, and the plate is what gets a reader to that doorway with the best odds.

None of this replaces the clinician. Eligibility, dosing, monitoring schedules, and any combination with GLP-1 therapy are specialist decisions, the drug’s pregnancy and interaction profile is the prescriber’s job, and a news congress is a reason for a question at a visit, never a self-prescription.

For a reader, the takeaway is that the first MASH drug is surviving contact with ordinary medicine: real patients, real clinics, biomarkers moving on the expected timeline, and the unexpected bonus signals in Lp(a) and portal-hypertension risk still awaiting their own trials, with the plate-and-exercise co-therapy unchanged as the foundation every result rests on.

The year’s arc closes neatly for this site’s purposes. A year ago the treatment story was a single approval and a promise; in 2026 it is real-world cohorts, cardiovascular secondary analyses, cirrhosis risk stratification, and cost-effectiveness models, and through every layer the base instruction is the same one printed on the drug’s own label and on every page of this site: diet and exercise first, and daily.

The patient-scheduling reality is the final practical note, because response timelines shape visits. A mean of 5.7 months to first biomarker assessment means a reader starting the drug this quarter should expect the first meaningful check around mid-treatment rather than week two, and the patience the timeline requires is exactly the patience the dietary co-therapy on the label rewards, since the plate and the pill both compound on the same months.